Lilly investing billions to prepare for overseas oral GLP-1 launches
BioSpace
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity dr
pharminent
April 14, 2026 (Last updated: April 14, 2026)
BioSpace
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity dr